Spots Global Cancer Trial Database for Modified Vaccinia Ankara (MVA) Vaccine Study
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Modified Vaccinia Ankara (MVA) Vaccine Study
Official Title: A Phase I, Dose Escalation Trial of Recombinant Modified Vaccinia Ankara (MVA)-Based Vaccine Encoding Epstein-Barr Virus Target Antigens
Study ID: NCT01256853
Interventions
Study Description
Brief Summary: This is a phase I, dose escalation trial of MVA-EBNA1/LMP2 vaccine across a pre-defined range of doses in patients in remission having had an EBV+ nasopharyngeal carcinoma (NPC).
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Department of Clinical Oncology, Prince of Wales Hospital, Hong Kong, , Hong Kong
Contact Details
Name: Anthony TC Chan, MD, FRCP
Affiliation: Department of Clinical Oncology, The Chinese University of Hong Kong
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
